ストックスクリーナーアプリを入手
1.17
4.88%
-0.06
前日終値:
$1.23
開ける：
$1.24
24時間の取引高:
122.78K
Relative Volume:
0.45
時価総額：
$36.50M
収益：
$1.05M
当期純損益:
$-48.82M
株価収益率:
-0.6393
EPS:
-1.83
ネットキャッシュフロー:
$-47.49M
1週間 パフォーマンス:
+1.74%
1か月 パフォーマンス:
-10.00%
6か月 パフォーマンス:
-44.81%
1年 パフォーマンス:
-82.43%
1日の値動き範囲:
$1.17
$1.26
1週間の範囲:
$1.15
$1.2848
52週間の値動き範囲:
$1.07
$10.24
Actinium Pharmaceuticals Inc Stock (ATNM) Company Profile
名前
Actinium Pharmaceuticals Inc
セクター
電話
646-767-3870
住所
275 Madison Avenue, 7th Floor, New York, NY
ATNM を他の銘柄と比較する
| 株式 | 価格 | 時価総額 | 収益 | 当期純利益 | 現金流量 | EPS |
|---|---|---|---|---|---|---|
ATNM
Actinium Pharmaceuticals Inc
|
1.17 | 36.50M | 1.05M | -48.82M | -47.49M | -1.83 |
|
VRTX
Vertex Pharmaceuticals Inc
|
484.24 | 124.35B | 11.02B | -535.60M | -978.00M | -2.20 |
|
REGN
Regeneron Pharmaceuticals Inc
|
700.33 | 76.56B | 14.20B | 4.41B | 3.54B | 38.28 |
|
ARGX
Argen X Se Adr
|
644.48 | 39.16B | 1.86B | -40.29M | -1.28B | -0.85 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
250.59 | 32.44B | 2.25B | -278.16M | -42.59M | -2.17 |
|
BNTX
Biontech Se Adr
|
120.01 | 28.77B | 3.30B | -501.07M | 1.03B | -2.1146 |
Actinium Pharmaceuticals Inc Stock (ATNM) Upgrades & Downgrades
| 日付 | アクション | アナリスト | 評価の変更 |
|---|---|---|---|
| 2024-08-07 | ダウングレード | B. Riley Securities | Buy → Neutral |
| 2024-05-14 | 開始されました | Stephens | Overweight |
| 2023-09-06 | 開始されました | HSBC Securities | Buy |
| 2023-02-21 | ダウングレード | William Blair | Outperform → Mkt Perform |
| 2022-09-08 | 開始されました | Cantor Fitzgerald | Overweight |
| 2022-08-25 | 開始されました | B. Riley Securities | Buy |
| 2020-11-05 | 開始されました | Alliance Global Partners | Buy |
| 2017-12-06 | 開始されました | B. Riley FBR, Inc. | Buy |
| 2017-10-23 | 再開されました | ROTH Capital | Buy |
| 2017-09-14 | 開始されました | Maxim Group | Buy |
| 2016-08-25 | 開始されました | ROTH Capital | Buy |
| 2016-02-29 | 開始されました | H.C. Wainwright | Buy |
| 2015-10-15 | 開始されました | FBR Capital | Outperform |
| 2014-10-01 | 開始されました | MLV & Co | Buy |
| 2014-07-22 | 開始されました | Canaccord Genuity | Buy |
すべてを表示
Actinium Pharmaceuticals Inc (ATNM) 最新ニュース
Actinium Pharmaceuticals (NYSE:ATNM) Shares Up 4.5% – What’s Next? - Defense World
ATNM SHAREHOLDER ALERT: Bronstein, Gewirtz and Grossman, LLC Announces an Investigation into Actinium Pharmaceuticals, Inc. and Encourages Stockholders to Contact the Firm! - ACCESS Newswire
Actinium Pharmaceuticals stock hits 52-week low at $1.1 - Investing.com
ATNM INVESTOR ALERT: Bronstein, Gewirtz and Grossman, LLC Announces an Investigation into Actinium Pharmaceuticals, Inc. and Encourages Investors to Contact the Firm Today! - ACCESS Newswire
Actinium Pharmaceuticals Inc (ATNM) vs. Its Peers: A Comparison - The News Heater
Actinium Pharmaceuticals, Inc. (NYSE:ATNM) Given Average Recommendation of “Moderate Buy” by Brokerages - Defense World
Barclays PLC Buys 32,784 Shares of Actinium Pharmaceuticals, Inc. (NYSE:ATNM) - Defense World
Actinium Pharmaceuticals (ATNM) Stock Price, News & Analysis - MarketBeat
Jane Street Group LLC Sells 24,392 Shares of Actinium Pharmaceuticals, Inc. (NYSE:ATNM) - Defense World
Geode Capital Management LLC Has $1.29 Million Stock Holdings in Actinium Pharmaceuticals, Inc. (NYSE:ATNM) - Defense World
Actinium Pharmaceuticals Announces Executive Appointments - Marketscreener.com
Actinium Pharmaceuticals, Inc. Appoints Richard Stone to Scientific Advisory Board - Marketscreener.com
Actinium Pharmaceuticals, Inc. Announces Executive Appointments - Marketscreener.com
Actinium Pharmaceuticals, Inc. (NYSE:ATNM) Given Consensus Rating of “Moderate Buy” by Analysts - Defense World
What Awaits Actinium In Q4? - RTTNews
Actinium Pharmaceuticals, Inc. Appoints Robert N. Daly as Vice President, Head of Clinical Operations - Marketscreener.com
Wellington Management Group LLP Acquires Shares of 59,608 Actinium Pharmaceuticals, Inc. (NYSE:ATNM) - Defense World
Charles Schwab Investment Management Inc. Has $136,000 Stock Position in Actinium Pharmaceuticals, Inc. (NYSE:ATNM) - Defense World
Targeted Alpha Therapy Market, Drugs Approval, Proprietary Technologies & Clinical Trials: 20+ Drugs of Targeted Alpha Therapy In Clinical Trials - GlobeNewswire Inc.
ATNM stock touches 52-week low at $1.17 amid market challenges - Investing.com Australia
My Top 2 Stock Picks For A 2025 Rebound - Seeking Alpha
Actinium Pharmaceuticals, Inc. (NYSE:ATNM) Receives Average Recommendation of “Moderate Buy” from Analysts - Defense World
Actinium stock plunges to 52-week low at $1.33 amid market challenges - Investing.com
Actinium Pharmaceuticals 2024 Stockholder Meeting Outcomes - TipRanks
Stephens Reaffirms “Overweight” Rating for Actinium Pharmaceuticals (NYSE:ATNM) - Defense World
Actinium Pharmaceuticals Continues R&D Focus Amid Financial Progress - TipRanks
Actinium Pharma keeps stock target with Buy rating on Q3 earnings - Investing.com UK
Actinium Pharmaceuticals Highlights Antibody Radiation Conjugate Program Developments and Reports Financial Results for the Third Quarter 2024 - PR Newswire
HC Wainwright Reaffirms “Buy” Rating for Actinium Pharmaceuticals (NYSE:ATNM) - Defense World
Actinium: Q3 Earnings Snapshot - mySA
Actinium Pharmaceuticals, Inc. (NYSE:ATNM) Receives $11.40 Consensus Price Target from Analysts - Defense World
Actinium Pharmaceuticals Inc (ATNM) Quarterly 10-Q Report - Quartz
Actinium Pharmaceuticals, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2024 - Marketscreener.com
Actinium Pharmaceuticals (NYSE:ATNM) Cut to Sell at StockNews.com - Defense World
Actinium Pharmaceuticals, Inc. (NYSE:ATNM) Given Average Rating of "Moderate Buy" by Brokerages - MarketBeat
Vanguard Group's Recent Acquisition in Actinium Pharmaceuticals - GuruFocus.com
Actinium Pharmaceuticals Appoints Accomplished Biopharma Industry Executive June Almenoff, M.D., Ph.D. to its Board of Directors - PR Newswire
Actinium Pharmaceuticals Appoints June Almenoff to its Board of Directors - citybiz
Adlai Nortye (NASDAQ:ANL) & Actinium Pharmaceuticals (NYSE:ATNM) Financial Comparison - Defense World
Amarin's Q3 Earnings In Line, Revenues Fall Shy of Estimates - MSN
The Manufacturers Life Insurance Company Invests $92,000 in Actinium Pharmaceuticals, Inc. (NYSE:ATNM) - Defense World
All You Need to Know About Actinium (ATNM) Rating Upgrade to Strong Buy - Yahoo Finance
Actinium Pharmaceuticals, Inc. (NYSE:ATNM) Receives Consensus Rating of “Moderate Buy” from Analysts - Defense World
Actinium Pharmaceuticals, Inc. (NYSE:ATNM) Receives Consensus Rating of "Moderate Buy" from Analysts - MarketBeat
Nurix Therapeutics Expands Its Board of Directors with the Addition of Drug Commercialization Expert Anil Kapur - The Manila Times
Hodgkin's Lymphoma Market Size, Share, Growth Insights - openPR
Renaissance Technologies LLC Invests $142,000 in Actinium Pharmaceuticals, Inc. (NYSE:ATNM) - Defense World
Actinium Pharmaceuticals (NYSE:ATNM) Lifted to Hold at StockNews.com - Defense World
Radiopharmaceuticals Market Size Projected to Soar to USD 16.6 Billion by 2032 with 10.4% CAGR – SNS Insider - GlobeNewswire
Comparing Actinium Pharmaceuticals (ATNM) and Its Competitors - Defense World
Radiopharmaceuticals Market Report, Size, Share, Growth, Trends, Industry Analysis, Forecast to 2033 - WhaTech
Actinium Pharmaceuticals Inc (ATNM) 財務データ
収益
当期純利益
現金流量
EPS
0.27%
3.05%
大文字化:
|
ボリューム (24 時間):